Genotyping for five SNPs plus family history is associated with a significant elevation in risk for prostate cancer. They do not improve prediction models for assessing who is at risk of getting or dying from the disease
Incorporating genetic information and family history in prostate cancer risk models can be useful for identifying younger men that might benefit from prostate-specific antigen screening
The authors developed a risk prediction algorithm for familial prostate cancer, taking into account genotyping of 26 SNPs and family history. The algorithm can be used on pedigrees of an arbitrary size or structure
Genotype influences the risk of prostate cancer per unit increase in prostate-specific antigen. Combined use could improve prostate specific antigen test performance
Genotyping can be used to adjust a man’s measured prostate-specific antigen concentration and potentially delay or prevent unnecessary prostate biopsies
When incorporated into a nomogram, genotype status contributed more significantly than PSA. The positive predictive value of the PSA test ranged from 42% to 94% depending on the number of variant genotypes carried
Using a genetic risk score, implemented in a risk-prediction model, there was a 22.7% reduction in biopsies at a cost of missing a PCa diagnosis in 3% of patients characterized as having an aggressive disease
Predicting biochemical recurrence after radical prostatectomy based on clinicopathological data can be significantly improved by including patient genetic information
Radical prostatectomy, the presence of pretreatment nocturia symptoms, and the variant alleles of TGFβ1 −509 C > T and codon 10 T > C are identified as factors involved in the development of acute radiation-induced nocturia when treated with IMRT
The XRCC1 Arg399Gln polymorphism is associated with an increase in risk for heterozygous individuals and for Gln carriers. For XRCC3 Thr241Met, the Met variant increases the risk in Met carriers
Presence of certain TGFβ1 genotypes is associated with the development of both erectile dysfunction and late rectal bleeding in patients treated with radiotherapy.
None of the previously reported associations were confirmed by this study, after adjustment for multiple comparisons. The value distribution of the SNPs tested against overall toxicity score was not different from that expected by chance
EGF functional polymorphism may contribute to earlier relapse in ABT patients, supporting the involvement of EGF as an alternative pathway in hormone-resistant prostatic tumors
Three SNPs in SLCO2B1 were associated with time to progression (TTP) on ADT. Patients carrying both SLCO2B1 and SLCO1B3 genotypes, which import androgens more efficiently, exhibited a median 2-year shorter TTP on ADT
TGFBR2-875GG homozygous patients have an increased risk of an early relapse after ADT. Combining clinicopathological and genetic information resulted in an increased capacity to predict the risk of ADT failure
KIF3C rs6728684, CDON rs3737336, and IFI30 rs1045747 genotypes remained as significant predictors for disease progression in multivariate models that included clinicopathologic predictors. A greater number of unfavorable genotypes were associated with a shorter time to progression and worse prostate cancer-specific survival during ADT.
Genetic variants in BNC2, TACC2, and ALPK1 are associated with clinical outcomes after ADT, with a cumulative effect on ACM following ADT of combinations of genotypes across the two loci of interest.
Genetic variants in ARRDC3, FLT1, and SKAP1 are significant predictors for PCSM and genetic variants in FBXO32 and FLT1 remained significant predictors for ACM. There was a strong combined genotype effect on PCSM and ACM.
Genetic variants in CASP3, BMP5, and IRS2 are associated with ACM. Genetic variation in BMP5 and IRS2 is significantly related to PCSM. Patients carrying a greater number of unfavorable genotypes at the loci of interest have a shorter time to ACM and PCSM during ADT.
When the sum of the risk genetic factors in each LD block was considered, patients with all the risk factors had significantly shorter cancer-specific survival than those with 0–2 risk factors.
Individuals carrying two copies of the polymorphic variant have a poor prognosis after docetaxel-based therapies compared with individuals carrying at least one copy of the allele.
Docetaxel-induced neuropathy, neutropenia grade, and overall survival could be linked to ABCB1 allelic variants (diplotypes).
Listing all the studies being discussed. From left to right: author (ref), genes/loci tested, number of patients included in the cohort, general endpoint of the study, significant SNPs, and conclusions.